Boston Scientific earnings expected to rise with Q1 report due April 22, amid recent clinical trial news.

Boston Scientific is set to report its Q1 earnings on April 22, with analysts forecasting earnings of 79 cents per share, up from 75 cents last year. Revenue is also expected to increase to $5.17 billion from $4.66 billion. The company recently shared data from its HI-PEITHO clinical trial on the EKOS Endovascular System for pulmonary embolism, which may impact investor sentiment. Several analysts have maintained Buy or Outperform ratings but have lowered price targets ahead of the earnings release.